Investing, page 10 of 18 — 24 articles published 2026-05-11 ~ 2026-05-12.
Vistra Corp (VST) stock outlook for 2026: Energy Harbor acquisition impact, Comanche Peak nuclear PPA strategy, AI hyperscaler long-term power deals, IRA nuclear PTC tailwinds, and three price scenarios with key financial data.
Gilead Sciences (GILD) stock outlook 2026: Biktarvy $3.4B quarterly, Yeztugo $166M debut, anito-cel CAR-T PDUFA Dec 23, 2026, 2.46% dividend yield, analyst target $152. Full pipeline, risks, and 3 price scenarios for US investors.
AstraZeneca (AZN) 2026 stock outlook covering Tagrisso, Enhertu, Datroway ADC pipeline, Farxiga CVRM growth, China VBP risk, and US Medicare price negotiation impact. Revenue data through Q1 2026.
NVO Novo Nordisk stock outlook for 2026. Wegovy and Ozempic franchise vs Eli Lilly competition, CagriSema REDEFINE trial setback, IRA Medicare drug pricing risk, amycretin pipeline, and three-scenario valuation analysis for US investors.
Lululemon Athletica (LULU) stock analysis for 2026 covering Power of Three ×2 strategy progress, the Mirror acquisition and exit lessons, men's line growth, China international expansion, and the competitive threat from Alo Yoga and Vuori.
KLA Corporation (KLAC) stock analysis for 2026 covering its near-monopoly in optical wafer inspection, why semiconductor scaling structurally increases process control demand, CEO transition impact, China export risks, and the case for holding KLAC in a long-term portfolio.
US Bancorp stock analysis for 2026: fifth-largest US commercial bank, three-segment business with Elavon payment services, MUFG Union Bank acquisition integration, CEO Gunjan Kedia strategy, dividend history, and 401(k)/Roth IRA suitability.
Capital One stock analysis for 2026: Discover Financial acquisition complete, becoming America's largest credit card lender by loans, founder-CEO Richard Fairbank's data model, consumer credit cycle risks, and tax treatment for US investors.
Danaher stock analysis for 2026: bioprocessing destocking cycle resolution, Cytiva and Pall recovery thesis, Abcam acquisition integration, Cepheid post-pandemic diagnostic growth, Danaher Business System advantage, and valuation framework for the recovery story.
Enbridge (ENB) stock analysis for 2026: the $14B Dominion gas utility acquisition, Mainline crude oil pipeline dominance, Canadian midstream structure (not a US MLP), dividend growth history, 401(k) vs Roth IRA tax treatment for Canadian dividends, and three investment scenarios.
Prologis (NYSE: PLD) stock analysis for 2026 covering the Duke Realty integration, data center campus pivot, embedded rent growth from mark-to-market lease rollovers, REIT tax treatment in IRAs, and the e-commerce vs. AI demand thesis for industrial real estate.
Lam Research (LRCX) stock analysis for 2026 covering the NAND and DRAM capex cycle recovery, HBM manufacturing complexity driving etch and deposition demand, CSBG recurring revenue, and the structural WFE oligopoly thesis.
Charles Schwab stock analysis for 2026: TD Ameritrade integration complete, 2023 cash sorting episode resolved, net interest income recovery trajectory, Rick Wurster CEO strategy, and what SCHW means for a US investor's Roth IRA or taxable account.
Intuitive Surgical stock analysis for 2026: da Vinci 5 FDA clearance and upgrade cycle implications, razor-and-blade model economics, Ion lung biopsy platform growth, competitive threats from Medtronic Hugo and J&J Ottava, and valuation framework for growth investors.
3M Company (MMM) stock analysis for 2026: the April 2024 Solventum healthcare spinoff, the $12.5B PFAS water utilities settlement, the $6B Combat Arms earplug settlement, CEO William Brown's restructuring agenda, and the Dividend King narrative after the dividend cut.
Realty Income (NYSE: O) stock analysis for 2026 covering 650+ consecutive monthly dividends, Dividend Aristocrat status, VEREIT and Spirit Realty acquisitions, UK expansion, REIT tax treatment in IRAs, and the interest rate sensitivity thesis.
Analog Devices (ADI) stock analysis for 2026 covering industrial semiconductor cycle recovery, Linear Technology and Maxim Integrated merger synergies, automotive BMS opportunity, and suitability for long-term dividend-growth portfolios.
Morgan Stanley stock analysis for 2026: three-segment business model, E*TRADE and Eaton Vance acquisition impact, Ted Pick CEO strategy, Fed rate sensitivity, and how MS fits a US investor's 401(k) or taxable portfolio.
Delta Air Lines (DAL) stock analysis for 2026: AmEx loyalty revenue stream, SkyMiles program valuation, Delta One premium cabin strategy, hub dominance at Atlanta ATL, cyclical risk factors, and 401(k) suitability for US investors.
HCA Healthcare (NYSE: HCA) stock analysis for 2026 covering Sunbelt population growth tailwinds, ambulatory surgery center expansion, GLP-1 long-term impact on surgical volumes, capital allocation, and bull/bear scenarios for US investors.
Mondelez International stock analysis for 2026: Oreo, Cadbury, Ritz brand portfolio, the direct GLP-1 threat to snack demand, Clif Bar and Ricolino acquisition impacts, cocoa cost pressure, and emerging market growth as the offsetting thesis.
American Tower (AMT) stock analysis for 2026: global tower footprint of ~220,000 sites, CoreSite data center acquisition, Big-3 US telco tenant concentration, REIT tax treatment for 401k and IRA investors, and three investment scenarios.
Cigna Group (NYSE: CI) stock analysis for 2026 covering the Evernorth PBM strategy, Medicare Advantage divestiture to HCSC, regulatory risk from FTC, GLP-1 drug cost exposure, and bull/bear scenarios for US investors.
Coca-Cola stock analysis for 2026 covering its 62-year dividend streak, GLP-1 weight-loss drug threats to beverage demand, asset-light bottling model, segment breakdown, and Roth IRA suitability for US income investors.